Clinical & Translational Omics Symposium

Dr. Yates’ research interests include development of integrated methods for tandem mass spectrometry analysis of protein mixtures, bioinformatics using mass spectrometry data, and biological studies involving proteomics. He is the lead inventor of the SEQUEST software for correlating tandem mass spectrometry data to sequences in the database and developer of the shotgun proteomics technique for the analysis of protein mixtures. His laboratory has developed the use of proteomic techniques to analyze protein complexes, posttranslational modifications, organelles and quantitative analysis of protein expression for the discovery of new biology. .

Jennifer Van Eyk, PhD, is an international leader in the area of clinical proteomics and her lab has focused on developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. Dr. Jennifer Van Eyk is currently the director of the Advanced Biosystems Research Institute at Cedars-Sinai Medical Center, LA and she also holds the inaugural Erika Glazer Endowed Chair in Women’s Heart Health

Jörg Hanrieder is one of the few researchers in the world who examines Alzheimer's plaques with an advanced technique where the plaques are stained with isotopes and then studied with imaging mass spectrometry and hyperspectral microscopy. Dr. Hanrieder is a chemist by definition, originally from Leipzig in Germany and a doctorate in Uppsala. Since 2015, he has been conducting research at the University of Gothenburg on the plaque formation that is characteristic of Alzheimer's disease.

Dr. Borchers' research involves the improvement, development, and application of proteomics and metabolomics technologies, especially quantitative techniques for clinical diagnostics; his research also involves the application of protein chemistry and mass spectrometry (MS), photoaffinity labelling, and molecular modelling to determine protein structure to problems in structural proteomics

Dr. Mohammed’s research interests are bottom-up and targeted proteomics, -omics data integration, scientific workflows, and eScience. In the past Yassene has also worked on distributed computing applications, data protection and data security, and biomedical image processing. Yassene is also heading the bioinformatics activities at the Proteomics Centre of the University of Victoria, Canada focusing on targeted proteomics bioinformatics, clinical applications of proteomics and statistical approaches for MRM and PRM analyses.

Dr. Glocker is head of the Proteome Center Rostock (PCR) since 1999. His research is dedicated to clinical proteomics with focus on polygenic diseases, such as autoimmune diseases, cancer, and metabolic disorders. He developed “Intact Transition Epitope Mapping (ITEM)” to decipher in one mass spectrometric experiment both, binding strengths and binding structure details on the sub-epitope level.

Dr. Alina Petre received her PhD from the University of Konstanz, DE in 2008 and completed her postdoctoral studies at Washington University in St. Louis, Mo, USA in 2011. Since 2012, she has been conducting research at her home institution, the 'Alexandru Ioan Cuza' University of Iasi, RO. Her current research interests focus on (i) protein and peptide chemistry, (ii) oxidative stress and neurodegenerative diseases, and (iii) rare disease diagnostics using multiplex-mass spectrometric strategy.

Dr. Thorsteinsdóttir research involves development of bioanalytical methods for metabolite profiling and quantification of clinical biomarkers in various biofluids utilizing chemometrics with the goal of improved clinical management of patients towards personalized patient care. Her research also involves the application of mass spectrometry-based metabolomics and targeted proteomics for early detection of breast cancer.

Dr. Rene Zahedi's research primarily focuses on understanding the causes of diseases using mass spectrometry to study changes in proteins related to diseases. He aims to identify biomarkers and validate them, study regulation of signaling pathways, and use protein mass spectrometry to study clinical samples. The focus is on translating methods into the clinic for the combined proteome and genome analysis of tumor samples to improve personalized medicine (proteogenomics)